IMRN
Immuron
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 0
Ample Liquidity
High Gross Profit Margin
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IMRN
Immuron Limited
An Australian developer of immunomodulator polyclonal antibodies that treats liver disease and infectious diseases
Pharmaceutical
Invalid Date
06/09/2017
NASDAQ Stock Exchange
7
06-30
Depository Receipts (Ordinary Shares)
Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia
Focus on providing oral immunotherapy to humans using dairy-derived antibody products
Immuron Limited was established in 1994 under the laws of Australia. The Company is a commercial and clinical-stage biopharmaceutical company with a patented technology platform focused on the development and commercialization of a new class of specifically targeted polyclonal antibodies that the Company believes address serious unmet medical needs.
Company Financials
EPS
IMRN has released its 2022 Q4 earnings. EPS was reported at -0.01, versus the expected 0, missing expectations. The chart below visualizes how IMRN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
